An overview of current clinical experience with strontium‐89 (Metastron®)
An overview of current clinical experience with strontium‐89 (Metastron®)
复制标题
锶-89 (Metastron®) 当前临床经验概述
DOI：
10.1002/pros.2990250708
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
S. Bos
中科院分区：
文献类型：
--
作者：
S. Bos
前列腺癌是男性最常见的肿瘤之一。在介绍中，50%的患者有晚期疾病，25%有骨转移。激素缓解是转移性骨痛的首选治疗，16 - 18个月的无疼痛缓解率为75%。化疗的二线治疗具有中度和短期效果。一旦内分泌治疗和化疗不再有效，放射治疗是复发性疼痛性骨转移的一个很好的选择。弥漫性疼痛性转移可以用半身照射治疗，有效率高达70%，但毒性相当大。
Prostate cancer is one of the most common tumors in men. At presentation, 50% of patients have advanced disease and 25% have bone metastases. Hormonal palliation is the treatment of choice for metastatic bone pain, with a pain‐free response rate of 75% for a period of 16‐18 months. Second‐line treatment with chemotherapy has a moderate and short‐term effect. Once endocrine therapy and chemotherapy cease to be effective, radiotherapy is a good option for recurrent painful bone metastases. Diffuse painful metastases can be treated with half‐body irradiation with a response rate of up to 70%, but there is considerable toxicity.